Osteoporosis Pharmacotherapy: Romosozumab, Denosumab, and Sequential Therapy Strategy

Romosozumab: Anti-Sclerostin Dual Mechanism

Osteoporosis pharmacotherapy has evolved from a single-agent approach — start a bisphosphonate and reassess in five years — to a sequential strategy that tailors therapy intensity to fracture risk and leverages different mechanisms of action in sequence. For the endocrinologist, rheumatologist, or primary care physician managing a patient with severe osteoporosis and a recent fracture, understanding how to deploy the newer anabolic agents (romosozumab, teriparatide, abaloparatide) and how to sequence them with antiresorptive therapy is now central to optimizing outcomes. The evidence strongly supports an anabolic-first approach for the highest-risk patients — starting with the most potent agents and transitioning to maintenance antiresorptive therapy rather than the reverse.

Romosozumab (210 mg SC monthly for 12 months) is a monoclonal antibody against sclerostin that uniquely increases bone formation while simultaneously decreasing bone resorption. The FRAME trial demonstrated a 73% reduction in new vertebral fractures versus placebo at 12 months (0.5% vs 1.8%, p<0.001)[1]. The ARCH trial, comparing romosozumab to alendronate, showed a 48% reduction in new vertebral fractures at 12 months (4.0% vs 7.5%) with romosozumab followed by alendronate[2]. BMD gains at the lumbar spine are approximately 13% at 12 months, the largest increase seen with any osteoporosis therapy.

Cardiovascular Safety Signal

The ARCH trial identified a cardiovascular safety signal with romosozumab versus alendronate (2.5% vs 1.9% adjudicated serious cardiovascular events at 12 months)[3]. This led to a boxed warning contraindicating romosozumab in patients with MI or stroke within the preceding year. The FRAME trial (romosozumab vs placebo) did not show this imbalance. Current guidance restricts romosozumab to patients at very high fracture risk without recent cardiovascular events, requiring individualized risk-benefit discussion.

Denosumab: Efficacy and the Rebound Problem

Denosumab (60 mg SC every 6 months) reduced hip fracture by 40%, vertebral fracture by 68%, and nonvertebral fracture by 20% over 3 years in the FREEDOM trial[4]. Ten-year extension data showed continued BMD gains and sustained fracture risk reduction. However, denosumab discontinuation triggers rapid bone loss (returning to pre-treatment BMD within 12-18 months) with a documented rebound vertebral fracture risk. Multiple case series report multiple vertebral fractures within 7-18 months of discontinuation. Current guidelines mandate transition to a bisphosphonate (zoledronic acid 5 mg IV preferred) upon denosumab cessation, timed to coincide with the next scheduled denosumab dose.

The Denosumab Discontinuation Conversation

Every clinician who starts a patient on denosumab must plan from the beginning for how to stop it. This is not a drug that can be simply discontinued when the patient requests it or when a clinical milestone is reached. The rebound bone loss is rapid, predictable, and dangerous — multiple vertebral compression fractures occurring in the 12-18 months following discontinuation are well documented. Patients should be counseled at the time of denosumab initiation that this is a commitment requiring either indefinite continuation or a carefully planned transition to bisphosphonate therapy. If a patient cannot commit to the monitoring and injection schedule required for denosumab, a bisphosphonate may be a more appropriate first choice even if the expected BMD gains are smaller.